EPISODE · Apr 20, 2022 · 17 MIN
Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care
from PeerVoice Clinical Pharmacology Video · host PeerVoice
Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care
Embed this episode
What this episode covers
Visit https://www.peervoice.com/ZDN860 to view the entire programme with slides. After completing “Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care”, participants will be able to: Discuss the latest guidance for treatment selection in relapsed/refractory multiple myeloma (RRMM); Evaluate the efficacy and safety data with anti-CD38 regimens for RRMM; Outline key factors that may guide anti-CD38–based treatment selection for patients with RRMM
Ready to play
Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care
No transcript for this episode yet
Similar Episodes
No similar episodes found.